Amphastar Pharmaceuticals, Inc. Shareholders' Equity
Amphastar Pharmaceuticals, Inc. (AMPH) had Shareholders' Equity of $445.52 million as of 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2022-03-11
- 2021-12-31: Stockholders' Equity Attributable to Parent $445.52M.
- 2021-09-30: Stockholders' Equity Attributable to Parent $430.18M.
- 2021-06-30: Stockholders' Equity Attributable to Parent $421.99M.
- 2021-03-31: Stockholders' Equity Attributable to Parent $405.56M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2021-12-31 | $445.52M 10-K · filed 2022-03-11 | |
| 2021-09-30 | $430.18M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $421.99M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $405.56M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $402.31M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $450.96M 10-Q · filed 2021-11-09 | $405.23M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $397.68M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $377.51M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $381.37M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $389.40M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $387.85M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $334.99M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $332.44M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $319.42M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $320.53M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $327.10M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $333.74M 10-K · filed 2019-03-15 | $337.33M 10-K · filed 2018-03-14 |
| 2017-09-30 | $330.65M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $333.31M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $325.56M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $329.25M 10-K · filed 2018-03-14 | |
| 2016-09-30 | $328.45M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $307.46M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $296.58M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $295.51M 10-K · filed 2018-03-14 | |
| 2015-09-30 | $283.79M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $285.26M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $279.28M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $281.86M 10-K · filed 2018-03-14 | |
| 2014-09-30 | $283.12M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $287.74M 10-Q · filed 2014-08-13 | |
| 2013-12-31 | $251.54M 10-K · filed 2017-03-15 | |
| 2012-12-31 | $233.44M 10-K · filed 2016-03-15 | |
| 2011-12-31 | $208.52M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |